KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) Return on Equity (2016 - 2025)

Inovio Pharmaceuticals' Return on Equity history spans 15 years, with the latest figure at 8.35% for Q3 2025.

  • For Q3 2025, Return on Equity fell 702.0% year-over-year to 8.35%; the TTM value through Sep 2025 reached 8.35%, down 702.0%, while the annual FY2024 figure was 1.16%, 36.0% down from the prior year.
  • Return on Equity for Q3 2025 was 8.35% at Inovio Pharmaceuticals, down from 2.32% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.25% in Q2 2021 and bottomed at 8.35% in Q3 2025.
  • The 5-year median for Return on Equity is 1.14% (2022), against an average of 1.47%.
  • The largest annual shift saw Return on Equity skyrocketed 94bps in 2021 before it crashed -702bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.71% in 2021, then plummeted by -60bps to 1.14% in 2022, then rose by 7bps to 1.06% in 2023, then plummeted by -44bps to 1.52% in 2024, then plummeted by -450bps to 8.35% in 2025.
  • Per Business Quant, the three most recent readings for INO's Return on Equity are 8.35% (Q3 2025), 2.32% (Q2 2025), and 1.7% (Q1 2025).